GBT to Announce Second Quarter 2021 Financial Results on Tuesday, August 3, 2021

Rhea-AI Summary

Global Blood Therapeutics (GBT) will report its second quarter 2021 financial results on August 3, 2021, after markets close. A conference call is scheduled for 4:30 p.m. ET on the same day to discuss results and provide a business update. GBT is known for its FDA-approved treatment for sickle cell disease, Oxbryta (voxelotor), and is advancing its pipeline with inclacumab in Phase 3 for pain crises and GBT021601 as a next-generation treatment. Visit gbt.com for details.

Positive

• Expected conference call on August 3, 2021, to provide financial insights and business updates.
• Successful launch of Oxbryta, the first FDA-approved treatment directly targeting sickle hemoglobin polymerization.
• Advancing development of inclacumab in Phase 3 and GBT021601 for sickle cell disease.

Negative

• None.

SOUTH SAN FRANCISCO, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report second quarter 2021 financial results on Tuesday, August 3, 2021, after U.S. financial markets close.

Management will host a conference call on Tuesday, August 3, 2021, at 4:30 p.m. ET to discuss second quarter 2021 financial results and to provide a general business update. To participate in the conference call, please dial 877-407-3982 (domestic) or +1 201-493-6780 (international). A live audio webcast of the conference call can be accessed on GBT’s website at www.gbt.com under the Investors section. An archived audio webcast will be available for one month following the event.

About Global Blood Therapeutics
Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta^® (voxelotor) tablets, the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in Phase 3 development to address pain crises associated with the disease, and GBT021601 (GBT601), the company’s next generation hemoglobin S polymerization inhibitor. In addition, GBT’s drug discovery teams are working on new targets to develop the next wave of potential treatments for SCD. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.

Contact:
Steven Immergut (media)
650-410-3258
simmergut@gbt.com

Courtney Roberts (investors)
650-351-7881
croberts@gbt.com

FAQ

When will Global Blood Therapeutics report its second quarter 2021 earnings?

GBT will report its second quarter 2021 financial results on August 3, 2021.

What time is the conference call for GBT's second quarter results?

The conference call is scheduled for 4:30 p.m. ET on August 3, 2021.

Where can I find the webcast for GBT's earnings call?

The live audio webcast can be accessed on GBT's website under the Investors section.

What is Oxbryta and its significance?

Oxbryta is the first FDA-approved treatment for sickle cell disease that directly inhibits sickle hemoglobin polymerization.

What other treatments is GBT developing?

GBT is advancing inclacumab in Phase 3 development and GBT021601 for sickle cell disease.